Form 4: GoodRx CAO Romin Nabiey Reports Equity Transactions

GoodRx Holdings, Inc.'s Chief Accounting Officer, Romin Nabiey, reported routine transactions involving the vesting of restricted stock units and subsequent share sales for tax purposes.

Summary

• Romin Nabiey, Chief Accounting Officer of GoodRx Holdings, Inc. (GDRX), reported transactions on September 8, 2025.
• Nabiey acquired 10,201 shares of Class A Common Stock through the vesting of restricted stock units (RSUs).
• Following this, 3,650 shares of Class A Common Stock were disposed of at a price of $4 per share to cover tax withholding obligations.
• An additional 2,232 shares of Class A Common Stock were acquired through the vesting of another RSU award.
• Subsequently, 799 shares of Class A Common Stock were disposed of at a price of $4 per share for tax withholding.
• After these transactions, Nabiey beneficially owns 145,276 shares of Class A Common Stock directly.
• The filing also details remaining derivative securities: 40,803 Restricted Stock Units from one award and 22,323 Restricted Stock Units from another award.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to equity compensation, which are neutral in terms of company performance or strategic direction.

Positives

• The vesting of restricted stock units indicates the continued retention and equity compensation of a key executive.
• The transactions are part of a pre-arranged plan (Rule 10b5-1(c)), suggesting a systematic approach to equity management rather than discretionary selling.

Negatives

• A portion of shares were sold, reducing the direct beneficial ownership of the Chief Accounting Officer, albeit for tax purposes.

Future Outlook

Future vesting schedules for restricted stock units are outlined, with one award continuing quarterly installments for 15 quarters following an initial vesting on December 8, 2022, and another commencing quarterly installments for 15 quarters after an initial vesting on June 8, 2024.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, common across all publicly traded companies, reflecting the standard practice of equity compensation for executives and the associated tax obligations upon vesting.

Stakeholder Impact

• Shareholders: Minimal impact as these are routine insider transactions related to equity compensation, not indicative of a change in company fundamentals or executive sentiment.

Next Steps

• Continued quarterly vesting of the remaining restricted stock units for the Chief Accounting Officer as per the established schedules.

Key Dates

Recommendation

The filing details routine insider transactions related to equity compensation, specifically the vesting of restricted stock units and subsequent sales for tax withholding. These transactions do not reflect a change in the company's fundamental outlook or the insider's long-term conviction, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

GoodRx, GDRX, Romin Nabiey, Insider Trading, Form 4, Restricted Stock Units, Equity Compensation, Chief Accounting Officer, Stock Transactions